This restricted adult expression underlies both its physiological specificity and its therapeutic relevance: the absence of ALK in most normal tissues renders it an attractive tumor-specific target, allowing for effective antitumor intervention while potentially minimizing on-target toxicity, thereby enhancing the feasibility and safety profile of ALK-targeted therapies. The gene discussed is ALK; the disease is neoplasm.